Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines.

导出 OA

翻译打印收藏纠错

作者： Neal D,Shore ^[1] ; Emmanuel S,Antonarakis ^[2] ; Michael S,Cookson ^[3] ; E David,Crawford ^[4] ; Alicia K,Morgans ^[5] ; David M,Albala ^[6] ; Jason,Hafron ^[7] ; Richard G,Harris ^[8] ; Daniel,Saltzstein ^[9] ; Gordon A,Brown ^[10] ; Jonathan,Henderson ^[11] ; Benjamin,Lowentritt ^[12] ; Jeffrey M,Spier ^[13] ; Raoul,Concepcion ^[14]

作者单位： Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, South Carolina. ^[1] Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland. ^[2] Department of Urology, University of Oklahoma, Oklahoma City, Oklahoma. ^[3] University of California, San Diego, LaJolla, California. ^[4] Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois. ^[5] Crouse Hospital, Syracuse, New York. ^[6] Willam Beaumont School of Medicine, Oakland University, Rochester, Michigan. ^[7] Beaumont Health, Royal Oak, Michigan. ^[8] Michigan Institute of Urology, Troy, Michigan. ^[9] Uropartners, Melrose Park, Illinois. ^[10] Urology San Antonio, San Antonio, Texas. ^[11] Rowan-School of Medicine, Stratford, New Jersey. ^[12] Jefferson Health New Jersey, New Jersey Urology, Sewell, New Jersey. ^[13] Regional Urology, LLC, Shreveport, Louisiana. ^[14] Chesapeake Urology Associates in Maryland, Chesapeake, Maryland. ^[15] Rio Grande Urology, El Paso, Texas. ^[16] Integra Connect, West Palm Beach, Florida. ^[17] Department of Urology, Vanderbilt University School of Medicine, Nashville, Tennessee. ^[18]

关键词 androgen deprivation therapy cancer consensus prostate